Hong Kong-listed Innovent Biologics Inc. is considering a licensing partnership to develop a cancer drug that’s showing ...

An announcement from Innovent Biologics ( ($HK:1801) ) is now available. Innovent Biologics has announced the approval of SYCUME®, China’s first ...

Innovent Biologics (HKEX: 01801) has gained approval in China for Sycume (teprotumumab), the country’s first IGF-1R antibody ...

Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and Eli Lilly.

Innovent Biologics and Roche have entered a partnership and exclusive licence agreement to accelerate the development of a delta-like ligand 3 (DLL3)-targeted antibody-drug conjugate (ADC ...

INNOVENT BIO (01801.HK) is working with a consultant to gauge the interest of global pharmaceutical companies in its ...

Innovent Technologies is redefining the landscape of contract machining and manufacturing with precision, efficiency, and adaptability.

(RTTNews) - Innovent Biologics Inc. (IVBXF.OB) announced that the New Drug Application or NDA for ipilimumab injection (anti-CTLA-4 monoclonal antibody) has been accepted by the Center for Drug ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vaxcyte (PCVX – Research Report), Envista ...

SAN FRANCISCO and SUZHOU, China, Dec. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...